JNJ looks promising for a breakoutJNJ looks promising for a breakout. With MRNA vaccines facing increased scrutiny in Europe, JNJ may benefit potentially.
JNJB34 trade ideas
Bullish on JNJJNJ is hovering at it's all time high, forming a cup & handle and just fired off a 'squeeze' (ala John Carter). So, I'm thinking it goes higher...
JNJ
Ascending TriangleLooks like earnings are over but JNJ is struggling at the resistance of the top trendline of the triangle.
An ascending triangle is still a triangle and can break either way.
The ascending triangle is a bullish continuation pattern and is characterized by a rising lower trendline and a flat upper trendline that acts as support. This pattern indicates that buyers are more aggressive than sellers as price continues to make higher lows. The pattern completes itself when price breaks out of the triangle in the direction of the overall trend.
The market should be in an uptrend when the ascending triangle appears. The ascending triangle starts to take on its form as the market enters the consolidation phase. While the market is consolidating, a rising trendline can be drawn by connecting the lows. This ascending trendline shows that buyers are slowly pushing the price up which provides further support for a bullish trading bias. The upper trendline acts as resistance. Price often approaches this level and bounces off until the breakout eventually occurs. After price posts a strong break above the upper trendline, traders will look for confirmation of the pattern via continued upward momentum. A clean break of the trendline with a trend in that direction is advisable before long entry.
Ascending triangles can break to the downside just as descending triangles can break to the upside.
Targets are calculated using the distance of the wide end of the triangle and projected upward from the triangle. Some use the bottom trendline for the projection and I have seen others use the bottom trendline.
You can place a stop somewhere under the triangle or inside where you see support. After a break of the upper trendline, some place the stop under the former top trendline of the triangle.
Price is close to the top bollinger band set on an 80 moving average.
No recommendation
JOHNSON & JOHNSON: DETAILED FUNDAMENTAL+FIBO ANALISY|LONG🔔Johnson & Johnson has been a profitable business to invest in for years. But its legal problems have grown steadily--the company has faced tens of thousands of lawsuits over talc alone.
And while so far the health care giant has managed to cope with its legal costs and remain profitable, that may not be the case in the future.
In addition, all these negative publications are not good for the Johnson & Johnson brand. The constant barrage of recalls and lawsuits could cause real, long-term damage. Can we still invest in this business, or have Johnson & Johnson's legal problems made this company a stock to be avoided at all costs?
Johnson & Johnson has been involved in numerous lawsuits in recent years. Most recently, earlier this month, the company announced a voluntary recall of certain Neutrogena and Aveeno sunscreens. Although benzene, a known carcinogen, is not in their composition, it was found in product testing. Johnson
& Johnson is recalling the products "for reasons of caution."
In addition, the U.S. Food and Drug Administration (FDA) issued a second warning regarding Johnson & Johnson's coronavirus vaccine. It states that the vaccine may increase a person's risk of developing a neurological disorder called Guillain-Barré syndrome. The agency had also previously issued a warning that the vaccine increases the risk of blood clots. (The FDA also issued warnings for Pfizer and Moderna's COVID-19 vaccines, saying they increase the risk of heart inflammation.)
These cases have not caused problems with Johnson & Johnson's financial performance - yet.
In 2020 and 2019, Johnson & Johnson's legal expenses totaled more than $5 billion. However, in each of those years, the company's net income was about $15 billion. And as a percentage of revenue, the company made an 18 percent profit - only slightly less than the 19 percent net income it achieved in 2018. From a purely financial standpoint, the company has yet to feel much of an impact on its bottom line. When Johnson & Johnson released its latest quarterly results on July 21, its earnings for the period ending April 4 looked higher than ever, at more than $6 billion.
But as problems mount, legal costs could rise sharply in the coming years. And rumor has it that the company is looking ahead to potentially limit some of that liability. According to a Reuters report, Johnson & Johnson is considering writing off liabilities related to baby powder talcum powder to a new business and then putting that business under bankruptcy protection. The move would help limit the company's legal liabilities related to the issue.
Johnson & Johnson is an incredibly profitable company, and its stock is the king of dividends you can count on for the foreseeable future - provided, of course, that legal bills don't begin to undermine the company's ability to meet those obligations. At present, that doesn't seem to be a problem.
However, investors should be careful not to rely solely on past performance or on the company's ability to weather the storm. The more problems become known, the more likely the company is to suffer financial losses in one form or another. We have no way of knowing whether a particular straw will be found that will break the camel's back, and it certainly seems unlikely now that Johnson & Johnson will not survive these problems, given its enormous size. But mere survival will not make this company a great investment. There are also intangibles to consider, such as the impact of bad headlines on the company's future and whether it might cause consumers to switch to competing brands. It, combined with potentially rising litigation costs, creates some long-term risk that investors shouldn't just ignore. And if a company is trying to dodge responsibility to consumers who have developed serious health problems related to talcum powder, it could alienate potential investors from an ethical standpoint.
While Johnson & Johnson is doing well right now, there are better options for investors that don't have nearly as much long-term risk.
Johnson and Johnson Analysis! Buy or Sell! The Covid-19 industryHello!
We can see that we have an up movement on the graph but let me show you some things:
- Ascending triangle is on formation (bull signal) and when the price breakout the neckline I am looking for 100% target.
- Falling wedge on formation (sell signal), just in case the price break the trend line, I will follow the price till the nest support and after make a move.
Remember: A trend it's more often continues !
Enjoy!
JNJ intraday ascending triangleJNJ is in a 7-month ascending triangle where we are testing resistance today with another ascending triangle.
Watch for increase in volume for continuation on breakout
entry: 173.22
JNJ Short this is a short play due to the fact they have a lawsuit about to hit. im looking for puts on HH and call the shorts. NYSE:JNJ
JNJ following earningsJNJ - Beat earnings estimates in sales and EPS. They had a great earnings and chart is looking very good here. Will be watching 171 as a key support on Monday and 172 area as resistance. Would like to get a dip buy to 171 as long as it holds but I will be looking at 175 calls for a potential swing trade with a PT of 175+. If we don’t hold 171, this could easily pullback to the ascending trend line support.
$JNJ with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $JNJ after a Positive Under reaction following its earnings release placing the stock in drift A
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
Are Covid Stocks Coming Back?If there is any hope for the S&P right now it may very well come from the healthcare sector with mega blue chip Johnson & Johnson.
JNJ has managed to put in consecutive higher highs and higher lows on the weekly, and now also is confirming support on the .618 fibonacci level at $165.40.
However, there appears to still be much selling pressure at just above $168, so don't be surprised if we continue to see consolidation for another a week or two before getting the confirmed breakout above our red resistance line at the aforementioned $168 price level.
If resistance at this level is broken, we will be seeing a possible retest of blue sky all time highs for the healthcare giant JNJ.
In the meantime, I am liking the idea of small longs along the .618 ($165.40) area as long as the upward sloping green trend is not violated.
JNJ forming a Ascending Triangle $$$ Watching JNJ forming a Ascending Triangle with multiple tops. Looking to enter above $170.Watching news carefully
JNJ - 4H :: Trendline + Support and Resistance Due to people's concern with possible variants, it is likely that there is an appreciation of the biotech market.
The take profit can be possible at $179
Market Alpha Long Term Analysis JNJSymbol: NYSE:JNJ
Indicators
Laguerre RSI
2 x Multi-Time Frame EMA
Comments: Looks like an ascending wedge here which typically breaks bearish. The Pattern had been pretty strong until a major violation took place. I expect further downside pressure.
We also just had mention of a new bankruptcy filing in attempt to avoid responsibility of over 30,000 cancer cases.
$JNJ | Model Prints New All Time High'sThe targets on this chart are produced by a proprietary model. Data is fed into the model, the output is the targets you see on the chart. The support zone is also defined by the model.
JNJ Will the $200 stop a protracted and non-corrective rally?Johnson & Johnson is a major manufacturer of cosmetic and sanitary products, as well as medical equipment and medicines. The company was founded in 1886.
In general, the history of the company is mega-successful. The corporation expanded through the purchases of competitors and gained more and more market share in its areas.
The company's progress is confirmed by the capitalization, which exceeds $430bn , as well as the graph of the JNJ share price, which is growing parabolic.
For 10 years, from 2002 to 2012, smart and patient investors recruited long positions in JNJ shares. During this period, the price traded in a broad consolidation of $46-71, growing volumes talked all - patience and everything will be)
From 2012 to the present, the value of JNJ shares has grown practically without correction.
Even during the Covid market plunge in February-March 2020, JNJ shares fell by only -29%. For example, then the S&P500 fell by -35%, the DJI index -38%, and the shares of the hype TSLA by as much as -60%.
The investors in this company knew and believed and they did not lose, because during the COVID-19 pandemic, a subsidiary of Johnson & Johnson, Janssen Pharmaceutica, developed a vaccine against this virus, which is certified for use in the USA and the EU, and the value of JNJ shares has renewed its absolute maximum.
Since the beginning of the year, JNJ's share price has been pushed towards the important $171 level . After the price fixes above this level, another upward impulse will take place.
We assume that it may be final before the start of a prolonged downward correction.
In the region of $195-200, it is better to fix the longs and look around, because the correction can be deep enough, and enough people who want to buy JNJ shares again may be in the $ 84-96 zone.
JNJits just idea... breakout or breakdown 👀 possible rising wedge, ascending triangle or still sideways...
JNJ - Ascending Triangle + Bad NewsI absolutely hate this company.
- Moving averages suggest bullish trend.
- 3rd attempt at major resistance.
- Doji Candle formed = change in trend/momentum.
- "Inside Day" pattern formed = Suggesting a continuation of the current trend. In this situation, it should continue the uptrend for a short period of time until a new pattern/confluence forms.
- However, JNJ can't catch a break regarding its vaccine. Issue after issue...
- Earnings Report - 7/21
This is a patience play. If you like to jump the gun, you could get burned...but with proper risk management, it may be worth the risk.
If you trade options:
Aggressive --> Play the Doji this week. 2 week expiration.
Moderate --> Wait for a few candles to form after today's doji. 1-2 month expiration.
Conservative --> Wait until after earnings. October expiration.
